Lipoprotein lipase (LPL)-deficient mice have been created by gene targeting in embryonic stem cells. At birth, homozygous knockout pups have threefold higher triglycerides and sevenfold higher VLDL cholesterol levels than controls. When permitted to suckle, LPL-deficient mice become pale, then cyanotic, and finally die at approximately 18 h of age. Before death, triglyceride levels are severely elevated (15,087 +/- 3,805 vs 188 +/- 71 mg/dl in controls). Capillaries in tissues of homozygous knockout mice are engorged with chylomicrons. This is especially significant in the lung where marginated chylomicrons prevent red cell contact with the endothelium, a phenomenon which is presumably the cause of cyanosis and death in these mice. Homozygous knockout mice also have diminished adipose tissue stores as well as decreased intracellular fat droplets. By crossbreeding with transgenic mice expressing human LPL driven by a muscle-specific promoter, mouse lines were generated that express LPL exclusively in muscle but not in any other tissue. This tissue-specific LPL expression rescued the LPL knockout mice and normalized their lipoprotein pattern. This supports the contention that hypertriglyceridemia caused the death of these mice and that LPL expression in a single tissue was sufficient for rescue. Heterozygous LPL knockout mice survive to adulthood and have mild hypertriglyceridemia, with 1.5-2-fold elevated triglyceride levels compared with controls in both the fed and fasted states on chow, Western-type, or 10% sucrose diets. In vivo turnover studies revealed that heterozygous knockout mice had impaired VLDL clearance (fractional catabolic rate) but no increase in transport rate. In summary, total LPL deficiency in the mouse prevents triglyceride removal from plasma, causing death in the neonatal period, and expression of LPL in a single tissue alleviates this problem. Furthermore, half-normal levels of LPL cause a decrease in VLDL fractional catabolic rate and mild hypertriglyceridemia, implying that partial LPL deficiency has physiological consequences.
P H Weinstock, C L Bisgaier, K Aalto-Setälä, H Radner, R Ramakrishnan, S Levak-Frank, A D Essenburg, R Zechner, J L Breslow
Title and authors | Publication | Year |
---|---|---|
Lipoprotein lipase (LpL) on the surface of cardiomyocytes increased lipid uptake and produced a cardiomyopathy
Hiroaki Yagyu, Guangping Chen, Masayoshi Yokoyama, Kumiko Hirata, Ayanna Augustus, Yuko Kako, Toru Seo, Yunying Hu, E. Peer Lutz, Martin Merkel, André Bensadoun, Shunichi Homma, Ira J. Goldberg |
Journal of Clinical Investigation | 2003 |
Suppression of skeletal muscle lipoprotein lipase activity during physical inactivity: a molecular reason to maintain daily low-intensity activity
L Bey, MT Hamilton |
The Journal of Physiology | 2003 |
Myocardial dysfunction and male mortality in peroxisome proliferator-activated receptor alpha knockout mice overexpressing lipoprotein lipase in muscle
C Nöhammer, F Brunner, G Wölkart, PB Staber, E Steyrer, FJ Gonzalez, R Zechner, G Hoefler |
Laboratory Investigation | 2003 |
Control of body weight: a physiologic and transgenic perspective
G Frühbeck, J Gómez-Ambrosi |
Diabetologia | 2003 |
HDL: The Metabolism, Function, and Therapeutic Importance
M Wang, MR Briggs |
Chemical Reviews | 2003 |
Fatty acids liberated from high-density lipoprotein phospholipids by endothelial-derived lipase are incorporated into lipids in HepG2 cells
JG Strauss, M Hayn, R Zechner, S Levak-Frank, S Frank |
Biochemical Journal | 2003 |
Lipoprotein lipase in lactating and neonatal northern fur seals: exploring physiological management of energetic conflicts
JE Mellish, TR Loughlin |
Comparative Biochemistry and Physiology - Part A Molecular & Integrative Physiology | 2003 |
APOA5—a recent addition to genes determining plasma triglycerides
PJ Talmud |
International Congress Series | 2003 |
Lung Biology in Health and Disease
N Zamel |
Lung Biology in Health and Disease: Experimental Models and Therapeutic Potential | 2003 |
Regulation of reverse cholesterol transport and clinical implications
DJ Rader |
The American Journal of Cardiology | 2003 |
STAT 1 binds to the LPL promoter in vitro
JC Hogan, JM Stephens |
Biochemical and Biophysical Research Communications | 2003 |
Transgenic Mice Expressing Lipoprotein Lipase in Adipose Tissue: ABSENCE OF THE PROXIMAL 3′-UNTRANSLATED REGION CAUSES TRANSLATIONAL UPREGULATION
LL Hensley, G Ranganathan, EM Wagner, BD Wells, JC Daniel, D Vu, CF Semenkovich, R Zechner, PA Kern |
The Journal of biological chemistry | 2003 |
Two cases with transient lipoprotein lipase (LPL) activity impairment: evidence for the possible involvement of an LPL inhibitor
H Nagasaka, H Kikuta, H Chiba, T Murano, H Harashima, A Ohtake, H Senzaki, N Sasaki, I Inoue, S Katayama, K Shirai, K Kobayashi |
European Journal of Pediatrics | 2003 |
Lipoprotein disorders and cardiovascular risk
J Genest |
Journal of Inherited Metabolic Disease | 2003 |